| Drug General Information |
| Drug ID |
D02ZQS
|
| Former ID |
DIB018022
|
| Drug Name |
GSK269962A
|
| Synonyms |
GSK-269962A; GSK269962; GSK 269962; GSK-269962; aminofurazanyl-azabenzimidazole 6n
|
| Drug Type |
Small molecular drug
|
| Indication |
Inflammatory disease [ICD9: 140-229, 147, 173, 573.3, 710-719; ICD10:C11, C44, K75.9, M00-M25]
|
Clinical trial |
[1]
|
|---|
| Structure |
|
Download
2D MOL
|
| Formula |
C29H30N8O5
|
| InChI |
InChI=1S/C29H30N8O5/c1-2-37-24-17-25(31-18-23(24)33-28(37)26-27(30)35-42-34-26)41-22-5-3-4-20(16-22)32-29(38)19-6-8-21(9-7-19)40-15-12-36-10-13-39-14-11-36/h3-9,16-18H,2,10-15H2,1H3,(H2,30,35)(H,32,38)
|
| InChIKey |
YOVNFNXUCOWYSG-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
24741762, 28702919, 40064106, 46514412, 50076551, 103504608, 103905674, 124349886, 135692870, 135697663, 137275847, 137618273, 141786191, 144116032, 152344382, 176485182, 180371700, 210275244, 210280884, 223704822, 224207972, 228010724, 241376758, 243106439, 249565717, 249618050, 252157709, 252159921, 252479007
|
| Target and Pathway |
| Target(s) |
Rho associated protein kinase 2 |
Target Info |
Inhibitor |
[1]
|
|---|
| Rho-associated protein kinase 1 |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
cGMP-PKG signaling pathway
|
|
cAMP signaling pathway
|
|
Chemokine signaling pathway
|
|
Sphingolipid signaling pathway
|
|
Vascular smooth muscle contraction
|
|
Wnt signaling pathway
|
|
Axon guidance
|
|
Focal adhesion
|
|
Platelet activation
|
|
Leukocyte transendothelial migration
|
|
Regulation of actin cytoskeleton
|
|
Oxytocin signaling pathway
|
|
Pathogenic Escherichia coli infection
|
|
Shigellosis
|
|
Salmonella infection
|
|
Pathways in cancer
|
|
Proteoglycans in cancerhsa04022:cGMP-PKG signaling pathway
|
|
TGF-beta signaling pathway
|
|
Proteoglycans in cancer
|
|
MicroRNAs in cancer
|
|
PANTHER Pathway
|
Cytoskeletal regulation by Rho GTPaseP00016:Cytoskeletal regulation by Rho GTPase
|
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
RhoA signaling pathway
|
|
Plasma membrane estrogen receptor signaling
|
|
Osteopontin-mediated events
|
|
PLK1 signaling events
|
|
PAR4-mediated thrombin signaling events
|
|
PAR1-mediated thrombin signaling events
|
|
Signaling events mediated by focal adhesion kinaseprlsignalingeventspathway:Signaling events mediated by PRL
|
|
Noncanonical Wnt signaling pathway
|
|
EPHB forward signaling
|
|
Thromboxane A2 receptor signaling
|
|
amb2 Integrin signaling
|
|
Integrins in angiogenesis
|
|
EPHA forward signaling
|
|
Stabilization and expansion of the E-cadherin adherens junction
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
N-cadherin signaling events
|
|
Reactome
|
EPHB-mediated forward signaling
|
|
EPHA-mediated growth cone collapse
|
|
G alpha (12/13) signalling events
|
|
Sema4D induced cell migration and growth-cone collapse
|
|
VEGFA-VEGFR2 Pathway
|
|
RHO GTPases Activate ROCKsR-HSA-111465:Apoptotic cleavage of cellular proteins
|
|
RHO GTPases Activate ROCKs
|
|
WikiPathways
|
G13 Signaling Pathway
|
|
Regulation of Actin Cytoskeleton
|
|
Focal Adhesion
|
|
JAK/STAT
|
|
Spinal Cord Injury
|
|
Pathogenic Escherichia coli infection
|
|
Leptin signaling pathway
|
|
Semaphorin interactions
|
|
Integrin-mediated Cell Adhesion
|
|
GPCR downstream signaling
|
|
MicroRNAs in cardiomyocyte hypertrophy
|
|
Androgen receptor signaling pathwayWP524:G13 Signaling Pathway
|
|
EGF/EGFR Signaling Pathway
|
|
TGF beta Signaling Pathway
|
|
AGE/RAGE pathway
|
|
Regulation of Microtubule Cytoskeleton
|
|
Apoptotic execution phase
|
|
Androgen receptor signaling pathway
|
| References |
| REF 1 | Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther. 2007 Jan;320(1):89-98. Epub 2006 Oct 3. |
|---|
